VEGFA and neoplasm: In colorectal cancer and other models, adenoviral and vaccinia backbones armed with soluble VEGF receptor inhibitors or anti-VEGF antibodies reduced endothelial proliferation, vessel permeability, and tumor perfusion, thereby limiting neovascularization and metastatic potential [19].